Versão HTML básica
382
Souza CA, Pagnano KB, Bendit I, Conchon M, Freitas CM, Coelho AM, Funke VA, Bernardo WM
Rev Bras Hematol Hemoter. 2012;34(5):367-82
PICO 14
Does adherence to Imatinib treatment have prognostic
impact?
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia,
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous,
Chronic OR Myelogenous Leukemia, Ph1-Positive OR
Leukemia, Myeloid, Ph1 Positive OR Myelogenous Leukemia,
Chronic OR Myeloid Leukemia, Philadelphia-Positive OR
Granulocytic Leukemia, Chronic) AND imatinib AND Prognosis
AND (Adherence OR Compliance)
PICO 15
Are prior cytogenetic responsewith Imatinib andperformance
status prognostic factors for response to second-line tyrosine
kinase inhibitors in patients resistant to Imatinib?
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia,
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous,
Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia,
Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic
OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic
Leukemia, Chronic) AND (CytogeneticAnalysis OR Cytogenetic*
OR performance status OR Karnofsky Performance Status) AND
Imatinibe AND (Nilotinib OR Dasatinibe) AND ((sensitiv*[Title/
Abstract] OR sensitivity and specificity[MeSH Terms] OR
diagnos*[Title/Abstract]ORdiagnosis[MeSH:noexp]ORdiagnostic
*[MeSH:noexp] OR diagnosis, differential[MeSH:noexp] OR
diagnosis[Subheading:noexp]) OR (prognos*[Title/Abstract]
OR (first[Title/Abstract] AND episode[Title/Abstract]) OR
cohort[Title/Abstract])) OR (evaluation study OR comparative
study OR epidemiologic methods))
PICO 16
When is it necessary to make an analysis of BCR-ABL
mutations in CML patients under treatment with tyrosine
kinase inhibitors?
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia,
Granulocytic, Chronic ORMyeloid Leukemia, Chronic OR Chronic
Myeloid Leukemia OR Leukemia, Myelocytic, Chronic OR Chronic
Myelocytic Leukemia OR Leukemia, Myelogenous, Chronic OR
Myelogenous Leukemia, Ph1-Positive OR Leukemia, Myeloid,
Ph1 Positive OR Myelogenous Leukemia, Chronic OR Myeloid
Leukemia, Philadelphia-Positive OR Granulocytic Leukemia,
Chronic) AND (Fusion Proteins, bcr-abl OR BCR-ABL OR BCR/
ABL) AND (Protein Kinase Inhibitors OR crizotinib OR Cyclin-
Dependent Kinase Inhibitor p15 OR Cyclin-Dependent Kinase
Inhibitor p18 OR Cyclin-Dependent Kinase Inhibitor p19 OR
Cyclin-Dependent Kinase Inhibitor p21 OR Cyclin-Dependent
Kinase Inhibitor p27 OR Cyclin-Dependent Kinase Inhibitor p57
OR Cyclin-Dependent Kinase Inhibitor Proteins OR dasatinib OR
erlotinib OR fasudil OR flavopiridol OR gefitinib OR Genistein OR
imatinib OR lapatinib OR roscovitine OR sorafenib OR vatalanib)
PICO 17
Does the diagnosis of mutations guide the choice of treatment
in imatinib-resistant patients?
((((Leukemia, Myelogenous, Chronic, BCR-ABL Positive
OR Leukemia, Myeloid, Philadelphia-Positive OR Leukemia,
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous,
Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia,
Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic
OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic
Leukemia, Chronic))) AND (((Fusion Proteins, bcr-abl)) OR
(Mutation*))) AND (((nilotinib OR dasatinib)) OR (bone marrow
transplantation))
PICO 18
How should monitoring of CML patients taking tyrosine
kinase inhibitors be performed?
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia,
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous,
Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia,
Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic
OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic
Leukemia, Chronic) AND (Protein Kinase Inhibitors OR Imatinib
OR Nilotinib OR Dasatinib) AND (Blood Cell Count OR
Cytogenetics OR Polymerase Chain Reaction OR Mutation* OR
In Situ Hybridization, Fluorescence) AND monitor*
PICO 19
When should bone marrow transplantation be indicated for
CML patients?
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia,
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous,
Chronic OR Myelogenous Leukemia, Ph1-Positive OR
Leukemia, Myeloid, Ph1 Positive OR Myelogenous Leukemia,
Chronic OR Myeloid Leukemia, Philadelphia-Positive OR
Granulocytic Leukemia, Chronic) AND BONE MARROW
TRANSPLANTATION AND (Therapy/broad[filter] OR
Comparative study)
xxx